ABSCIENCES (EPA:AB) AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
Transparency directive : regulatory news
13/03/2023 18:09